
Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas
Panelists discuss how several studies evaluating bispecific therapies in earlier lines of therapy for diffuse large B-cell lymphoma and follicular lymphoma suggest that patients with high-risk or relapsed/refractory disease are most likely to benefit from these treatments.
Episodes in this series

Video content above is prompted by the following:
Several studies are evaluating the use of bispecific therapies in earlier lines of therapy for both diffuse large B-cell lymphoma and follicular lymphoma. What patient populations are most likely to benefit from bispecific therapies in earlier lines of therapy?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.